Artelo Biosciences Q2 2023 Earnings Report

Artelo Biosciences EPS Results

• Actual EPS: -$3.36
• Consensus EPS: -$5.58
• Beat/Miss: Beat by +$2.22
• One Year Ago EPS: N/A

Artelo Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Artelo Biosciences Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: N/A
• Conference Call Date: Thursday, August 10, 2023
• Conference Call Time: 7:00AM ET

Artelo Biosciences (NASDAQ:ARTL), a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.